Profiel
Kathryn M.
McNeil worked as Head-Investor & Media Relations at Chelsea Therapeutics International Ltd. from 2009 to 2012.
She was also VP-Investor Relations & Public Relations at Novelos Therapeutics, Inc. from 2013 to 2014, and VP-Investor Relations & Corporate Communications at Cellectar Biosciences, Inc. from 2013 to 2015.
In 2017, she worked as Head-Communication & Investor Relations at Invitae Corp.
Ms. McNeil obtained an undergraduate degree from Wesleyan University.
Eerdere bekende functies van Kathryn M. McNeil
| Bedrijven | Functie | Einde |
|---|---|---|
| INVITAE CORPORATION | Public Communications Contact | 01-04-2018 |
| CELLECTAR BIOSCIENCES, INC. | Investor Relations Contact | 28-07-2015 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Investor Relations Contact | 12-02-2014 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Investor Relations Contact | - |
Opleiding van Kathryn M. McNeil
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company developing and commercializing therapeutics for a variety of human diseases | Health Technology |
Invitae Corp.
Invitae Corp. Medical/Nursing ServicesHealth Services Provides genetic testing services for patients | Health Services |
Wesleyan University
Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Health Technology |
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer | Health Technology |
















